EP0723460A4 - Gene therapy of the nervous system - Google Patents

Gene therapy of the nervous system

Info

Publication number
EP0723460A4
EP0723460A4 EP94930498A EP94930498A EP0723460A4 EP 0723460 A4 EP0723460 A4 EP 0723460A4 EP 94930498 A EP94930498 A EP 94930498A EP 94930498 A EP94930498 A EP 94930498A EP 0723460 A4 EP0723460 A4 EP 0723460A4
Authority
EP
European Patent Office
Prior art keywords
nervous system
gene therapy
therapy
gene
nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94930498A
Other languages
German (de)
French (fr)
Other versions
EP0723460A1 (en
Inventor
Zvi Ram
R Michael Blaese
Edward H Oldfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP0723460A1 publication Critical patent/EP0723460A1/en
Publication of EP0723460A4 publication Critical patent/EP0723460A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP94930498A 1993-10-01 1994-09-28 Gene therapy of the nervous system Withdrawn EP0723460A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13108593A 1993-10-01 1993-10-01
US131085 1993-10-01
PCT/US1994/010977 WO1995009654A1 (en) 1993-10-01 1994-09-28 Gene therapy of the nervous system

Publications (2)

Publication Number Publication Date
EP0723460A1 EP0723460A1 (en) 1996-07-31
EP0723460A4 true EP0723460A4 (en) 1998-09-30

Family

ID=22447805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94930498A Withdrawn EP0723460A4 (en) 1993-10-01 1994-09-28 Gene therapy of the nervous system

Country Status (4)

Country Link
EP (1) EP0723460A4 (en)
JP (1) JPH09505561A (en)
CA (1) CA2171109A1 (en)
WO (1) WO1995009654A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246252T1 (en) 1994-08-16 2003-08-15 Crucell Holland Bv ADENOVIRUS-DERIVED RECOMBINANT VECTORS FOR GENE THERAPY
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1998032869A1 (en) * 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
BR9813930A (en) 1997-11-06 2006-12-19 Chiron Spa neisserial antigen
EP1047784B2 (en) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
CA2323067A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB2397063A (en) * 1999-10-21 2004-07-14 Cedars Sinai Medical Center A medicament comprising a cytotoxic pro drug activated by HSV TK
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
EP2975127A1 (en) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2335723A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CN104292321A (en) 2004-03-29 2015-01-21 株式会社嘉尔药物 Novel modified galectin 9 protein and use thereof
WO2006020949A2 (en) 2004-08-12 2006-02-23 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
WO2015013148A2 (en) * 2013-07-26 2015-01-29 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
AU2021336570A1 (en) 2020-09-02 2023-02-09 Fredrik JOHANSSON SWARTLING Predicting cancer relapse and treatment of cancer diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREAKEFIELD ET AL: "GENE TRANSFER INTO THE NERVOUS SYSTEM", MOLECULAR NEUROBIOLOGY, vol. 1, 1987, pages 339 - 371, XP002072764 *
MURASZKO ET AL: "PHARMACOKINETICS AND TOXICOLOGY OF IMMUNOTOXINS ADMINISTERED INTO THE SUBARACHNOID SPACE IN NONHUMAN PRIMATES AND RODENTS", CANCER RESEARCH, vol. 53, 1993, pages 3752 - 3757, XP002072533 *
RAM ET AL: "INTRATHECAL GENE THERAPY FOR MALIGNANT LEPTOMENINGEAL NEOPLASIA", CANCER RESEARCH, vol. 54, 15 April 1994 (1994-04-15), pages 2141 - 2145, XP002072534 *
See also references of WO9509654A1 *

Also Published As

Publication number Publication date
WO1995009654A1 (en) 1995-04-13
JPH09505561A (en) 1997-06-03
EP0723460A1 (en) 1996-07-31
CA2171109A1 (en) 1995-04-13

Similar Documents

Publication Publication Date Title
EP0723460A4 (en) Gene therapy of the nervous system
AU3972893A (en) Gene therapy using the intestine
HK1024622A1 (en) Il 12 for the gene therapy of tumours
EP0789592A4 (en) Ocular gene therapy
GB9622500D0 (en) Therapeutic gene
HK1008979A1 (en) Gene transfer-mediated angiogenesis therapy
EP0688358A4 (en) Improved vectors for gene therapy
GB9307013D0 (en) Therapeutic combinations
GB2281202B (en) Physical therapy bolster
HU9401601D0 (en) Therapeutic method
PH31659A (en) Therapeutic nucleotides.
GB9310441D0 (en) Gene therapy
ZA946217B (en) Therapeutic combination
GB2289046B (en) An effluent treatment system
AU5165993A (en) Pp14-based therapy
GB9310889D0 (en) Neuro-muscular stimulator
GB9521711D0 (en) Gene therapy
GB9520433D0 (en) Gene therapy
GB9418696D0 (en) Gene therapy
GB9323437D0 (en) Therapy
GB9304024D0 (en) Tumour therapy
GB9219754D0 (en) Aids therapy
GB9308962D0 (en) Therapeutic agetns
GB9306646D0 (en) Therapeutic agetns
GB2333527B (en) Therapeutic gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960318

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980818

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970203